You are here
Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety
American Journal of Obstetrics and Gynecology, Volume 214, Issue 1, January 2016, Pages 45 - 56
Progestogens are the first drugs to demonstrate reproducibly a reduction in the rate of early preterm birth. The efficacy and safety of progestogens are related to individual pharmacologic properties of each drug within this class of medication and characteristics of the population that is treated. The synthetic 17-hydroxyprogesterone caproate and natural progesterone have been studied with the use of a prophylactic strategy in women with a history of preterm birth and in women with a multiple gestation. Evidence from a single large comparative efficacy trial suggests that vaginal natural progesterone is superior to 17-hydroxyprogesterone caproate as a prophylactic treatment in women with a history of mid-trimester preterm birth. Progestogen therapy is indicated for women with this highest risk profile based on evidence from 2 trials. A therapeutic approach based on the identification of a sonographic short cervix has been studied in several phase III trials. Independent phase III trials and an individual patient metaanalysis suggest that vaginal progesterone is efficacious and safe in women with a singleton and a short cervix. Two trials that tested 17-hydroxyprogesterone caproate in women with a short cervix showed no benefit. No consistent benefit for the prophylactic or therapeutic use of progestogens has been demonstrated in larger trials of women whose pregnancies were complicated by a multiple gestation (twins or triplets), preterm labor, or preterm rupture of membranes. Unfortunately, several large randomized trials in multiple gestations have identified harm related to 17-hydroxyprogesterone caproate exposure, and the synthetic drug is contraindicated in this population. The current body of evidence is evaluated by the Grading of Recommendations Assessment, Development, and Evaluation guidelines to derive the strength of recommendation in each of these populations. A large confirmatory trial that is testing 17-hydroxyprogesterone caproate exposure in women with a singleton pregnancy and a history of preterm birth is near completion. Additional study of the efficacy and safety of progestogens is suggested in well-selected populations based on the presence of biomarkers.
Key words: 17-OHPC, adverse event, biomarker, cervical length, early preterm birth, history of preterm birth, metaanalysis, multiple gestation, pharmacodynamics, progestogens, safety, short cervix, twin gestation.
The only class of medication to demonstrate significant reductions repeatedly in the rate of early preterm birth are progestogens, natural progesterone or the synthetic 17-hydroxyprogesterone caproate (17-OHPC).1 and 2 Published guidelines have provided recommendations regarding their use.3, 4, and 5 These agents are prescribed in asymptomatic patients who are at increased risk for spontaneous preterm birth that was determined by obstetric history or a sonographic short cervix. The risk for recurrent preterm birth varies depending on the gestational age at previous delivery, number of previous preterm births, whether an intervening term delivery has occurred, and the classification of the previous preterm birth as either spontaneous or indicated.6, 7, 8, and 9 The risk for preterm birth based on the cervical length also varies based on the gestational age a short cervix is identified and the population in which the measurement is obtained.10, 11, and 12 Defining an optimal strategy for preterm birth prevention based on a risk factor or a biomarker for a presumed pathophysiologic process (a decline in progesterone action) or both can improve the risk-benefit ratio, lower health care costs, and enhance translation of scientific findings along particular paths.13 and 14
Drug development pathways initially have focused on selecting candidate compounds by generating an animal model of disease or by defining molecular responses to exposures. Subsequent phase I and II studies provide information regarding pharmacokinetics, dose response, initial safety observations, and the potential to alter clinically meaningful endpoints (see Glossary of terms). Ideally, phase III trials should then evaluate efficacy and safety in a well-selected candidate population to yield significant improvement in the best chosen, clinically important outcome. After efficacy is validated (often by replication), the indication for use may be expanded by additional trials that consider the effectiveness and safety profile of the intervention. This sequence for drug development was not used when exploring the efficacy of progestogens to prevent preterm birth; indeed, this systematic approach has been used rarely in obstetrics. Hence, interventions in obstetrics should undergo more frequent reevaluation while being implemented into clinical practice. This review addresses the efficacy and safety of progestogen use, given recent experimental observations regarding pharmacodynamics and the evolving understanding of risk-benefit provided from trials and metaanalysis.
Phase I trial
A study early in the development process of an intervention aimed to describe pharmacokinetics, suggest optimal dose, identify remarkable harms/frequent adverse events, or establish the feasibility of treatment.
Phase II trial
A study aimed to estimate the activity of the drug (explore surrogate endpoints), compare dosing schedules to alter pharmacodynamics, or provide an estimate for demonstrating significant differences in clinically important endpoints.
Phase III trial
A study aimed to demonstrate superiority of an intervention (over placebo or other comparator) to alter clinically important endpoints or noninferiority (an intervention is no worse than another by a specified margin), in conjunction with an aim to better define the frequency of adverse events or harm. To accomplish both aims, phase III studies most commonly have a sample size in the hundreds or thousands.
The identification of any changes within the body that are related to a drug exposure.
This is a function of a test article under idealized circumstances in which the exposure is more controlled by investigators who include stricter inclusion and exclusion criteria, standardized provider skill assessment or testing, and uniform response to clinical circumstances. This determination is potentially a product of phase III trials.
This is a function of a test article under clinical use conditions. This determination is potentially a product of trials with pragmatic design features that include limited exclusion criteria and few restrictions on additional therapies in response to clinical circumstances.
Pharmacodynamics and their implications for treatment
The mechanism of action for supplemental progestogens to improve pregnancy outcome likely relies on increased interaction between progesterone receptors and their ligands. Presumably, the enhanced receptor-ligand interaction alters ≥1 hormone-mediated physiologic properties aimed at meeting the dynamic functional demands placed on tissues of the reproductive tract during pregnancy. Each tissue of the reproductive tract, the chorioamniotic membranes, and the fetus express progesterone receptors with potential physiologic activities.15, 16, and 17 The potential to augment cellular and tissue functions that are mediated by progesterone receptors beyond that achievable by the hormone that is produced from the preterm placenta alone has been termed the progestogen hypothesis.18
If increasing the bioavailability of progesterone for its receptors within the reproductive tract is the therapeutic target, then this goal may be realized through supplementation that increases concentration within these target tissues or by reduction of progesterone degradation. Therefore, a potential alternative site of action for progestogens is within the liver. Caritis et al19 reported a linear, highly significant positive correlation between serum 17-OHPC concentration and serum progesterone concentration (R2 = 0.46; P < .0001). An association between 17-OHPC exposure and an increased serum progesterone concentration has also been observed in 2 animal models, 1 of which was a primate model (both P < .01).20 and 21 Furthermore, 17-OHPC and progesterone have been shown to competitively interact with the cytochrome P450 3A4 enzyme (CYP 3A4) in human liver microsome preparations.22 Of note, supplemental progestogens do not act to increase the placental production of progesterone or cross-react with other steroid hormone receptors.19 and 23 Therefore, data support 2 potential sites of action for progestogens to enhance the progesterone receptor-ligand interaction; however, each strategy may have different capabilities to alter progesterone actions within the reproductive tract.
Both progesterone and 17-OHPC have been shown to alter progesterone receptor and cellular activity, but the relative binding affinity of 17-OHPC for nuclear progesterone receptors A and B is only 26-30% that of natural progesterone.23, 24, and 25 This lower binding affinity raises the question whether this synthetic drug can act with equal efficacy as natural progesterone to influence receptor-mediated activities directly within the reproductive tract. In addition to the pharmacologic properties of these drugs and their site of action, other factors influence treatment response to progestogens. The population that is treated is the most important consideration because a variation in response to these agents has been demonstrated in different populations. Furthermore, within populations, individual patient characteristics appear to alter the effectiveness of this treatment strategy. In support of the latter construct, Manuck et al26 demonstrated a variable response to 17-OHPC exposure, based on the progesterone receptor genotype.
In an informative experiment in a pregnant murine model, Nold et al20 assessed differences in gene transcription after supplemental progesterone or 17-OHPC exposure in select pathways that are implicated in the pathophysiology of preterm delivery. The effects of 17-OHPC and progesterone in the cervix and myometrium were assessed. These investigators found progesterone, but not 17-OHPC, had a treatment effect that was localized to the cervix. Specifically, defensin-1, an antimicrobial peptide, was significantly up-regulated by supplemental progesterone exposure. These data suggest that a potential relationship exists among mucosal integrity, inflammation, cervical remodeling, spontaneous preterm labor, and this treatment.
A detailed series of experiments that tested the immune response to supplemental progestogens was performed recently by Furcron et al27 in a pregnant murine model. These investigators also observed that vaginal progesterone, but not 17-OHPC, was associated with beneficial effects. The immune response to natural progesterone alone resulted in a significant increase in the proportion of decidual CD4+ Tregs, a reduction in the proportion of macrophages in decidual tissues, and a reduction of active MMP-9+ cells in the cervix. Furthermore, vaginal progesterone was shown to protect against endotoxin-induced preterm birth (effect size, 50%; P = .0008). Although additional study of supplemental progestogens is needed, current evidence suggests that the alteration in the immune response is an important mechanism of action for these agents.
A paucity of experimental data is available to describe the effects of supplemental progestogens on human tissues at preterm gestational ages. The treatment response to a dose of supplemental progestogens may differ throughout gestation because placental production of the hormone varies so remarkably based on gestational age.28 A study by Ruddock et al29 incubated myometrial strips that were obtained from term cesarean deliveries with different progestogens. Progesterone treatment was found to induce relaxation of the smooth muscle; 17-OHPC exposure stimulated myometrial activity. Another study from term cesarean deliveries by Kumar et al30 noted that exposure to progesterone significantly reduced membrane weakening.
In summary, the experimental observations in human tissue and animal models demonstrate that (1) sites of action within the reproductive tract and liver are possible after exposure to these distinct progestogens, (2) the cervix or decidua are likely primary targets to prevent preterm birth by these agents, but other activities are possible, and (3) natural progesterone may be the superior progestogen to alter gene transcription and cellular physiologies to vary the immune response to prevent spontaneous preterm birth.
Clinical trial data that has assessed pharmacodynamic responses to supplemental progestogens has focused on cervical length measurement. A planned secondary analysis of the largest trial to date measured cervical length at enrollment and at 28 weeks gestation in asymptomatic singletons.31 The difference in measurement at these time-points was significantly smaller, and the cervical length at 28 weeks gestation was significantly longer in women who were treated with progesterone. A slower rate of cervical change was also demonstrated in a randomized trial testing a higher dose of 17-OHPC (682 mg/wk) in a symptomatic population with an episode of preterm labor.32 However, 2 retrospective studies that evaluated prophylactic treatment with 250 mg/wk of 17-OHPC did not identify a treatment effect on cervical length.33 and 34 Regarding myometrial activity, a large observational study demonstrated a significant increase in contraction frequency after exposure to 17-OHPC, whereas natural progesterone exposure has been shown to significantly decrease contraction frequency.35 and 36 Therefore, clinical data also suggest that these 2 compounds should not be considered equivalent regarding their actions on the reproductive tract functions.37
Is there evidence of superiority between progestogens?
Given its results, the phase III study by Meis et al38 stimulated design and execution of numerous additional large trials that tested progestogens in a variety of populations. A significant reduction in recurrent preterm birth (36.3% vs 54.9%; relative risk [RR], 0.66 [95% confidence interval (CI), 0.54–0.81]) was demonstrated with exposure to 17-OHPC in addition to fewer deliveries at <35 weeks gestation (20.6% vs 30.7%; RR, 0.67 [95% CI, 0.48–0.93]). Although this trial demonstrated efficacy, several concerns have been identified that include an imbalance between study groups, patient selection and generalizability of its conclusions because of the higher rate of preterm birth in the placebo group compared with other prospective observational studies, and the vehicle (castor oil) for this progestogen. Despite randomization, the women in the placebo group had a significantly higher mean number of previous preterm births (1.6 ± 0.9 vs 1.4 ± 0.7; P = .007) and a significantly greater percentage of these women had >1 previous preterm delivery before enrollment, (41.2% vs 27.7%; P = .004 by chi square based on data presented). A confirmatory phase III trial was required by the Food and Drug Administration (FDA) for its current conditional approval, given these concerns. This study has a planned enrollment of 1707 women and is intended to replicate the efficacy of 17-OHPC as a prophylactic treatment in women with a history of preterm birth. (The PROLONG Trial-clinicaltrials.gov/ct2/show/NCT01004029) This study will also better assess the safety of the drug in singleton gestations, given its planned sample size.
The FDA has also evaluated vaginal progesterone that is indicated for women with a sonographic short cervix.39 The marketing of natural progesterone indicated for this biomarker was not approved. In their analysis, the Agency publicly focused on treatment site interaction, the selection of statistical tests, and potential confounding variables. An independent review of the trial data differed from the FDA analysis and noted treatment benefit.40 Unfortunately, data from phase III trials by Fonseca et al41 and O’Brien et al42 was discounted during the review process, and a participant level metaanalysis by Romero et al43 was also inappropriately criticized. To date, the actions of the FDA regarding progestogens have resulted in approval of a synthetic hormone that is indicated for a risk factor, but the parent natural hormone remains unapproved when indicated for a well-validated biomarker. Therefore, these regulatory actions may have given the impression that 17-OHPC is the superior progestogen and that a treatment strategy based on a prophylactic approach is better. However, further assessment is needed.
The largest comparative efficacy trial to date that has tested the relative efficacy of progestogens for preterm birth prevention was performed by Maher et al.44 This trial enrolled women with more selective inclusion criteria and who were at greater risk for recurrent preterm birth. Inclusion criteria included (1) had a history of ≥1 mid-trimester preterm births or (2) had a cerclage suture placed in a previous pregnancy. Cerclage was indicated per their protocol for an obstetric history of ≥2 mid-trimester preterm births or cerclage placement in a previous pregnancy. Women with a short cervix <25 mm at <19 weeks gestation and those with or planning a cervical cerclage were excluded. This trial enrolled 518 women; outcomes were available for 253 participants who were administered 90 mg vaginal progesterone daily and 249 participants who underwent weekly intramuscular injections of 250 mg 17-OHPC. The compliance with each treatment was excellent. A significant reduction in preterm birth at <34 weeks gestation was observed with supplemental vaginal progesterone (16.6% vs 25.7%; RR, 0.58; 95% CI, 0.37–0.89; P = .02), and significantly lower rates of delivery at <32 and <28 weeks gestation were secondary findings. Pregnancy duration was in favor of natural progesterone by Kaplan-Meier analysis (P = .0023). Finally, the number of neonatal intensive care unit admissions was lower with progesterone (15.4% vs 25.7; P = .006). Therefore, this study found that the efficacy of vaginal progesterone was superior to 17-OHPC in the prevention of recurrent preterm birth in a higher risk, compliant population.
One potential explanation for decreased efficacy of the synthetic drug is that 630 mg/week of natural progesterone was administered vs 250 mg/week of 17-OHPC. In support of this concern, Caritis et al45 found that the women in the lowest quartile of serum 17-OHPC concentration had higher rates of recurrent preterm birth. These data suggest, for singletons, that the optimal dose of 17-OHPC has not been identified and may vary based on factors such as body mass index, coexisting drug exposures, or innate differences in hepatic metabolism that may alter the serum concentration of this synthetic progestogen and/or natural progesterone.45 and 46 If monitoring serum 17-OHPC concentration is ultimately deemed necessary to optimize treatment, then intramuscular dosing of this synthetic drug will be more difficult and costly. The vaginal route of drug delivery likely results in a greater concentration of supplemental progesterone within the uterus and cervix compared to serum, if vaginal absorption during pregnancy is similar to nonpregnant women. A “first uterine pass effect” has been documented in nonpregnant women.47 and 48
The comparative efficacy study by Maher et al44 also addresses a potential misperception that these individual progestogens are exclusively efficacious in particular populations that are at risk. Because both of these progestogens are members of the same class of drugs, most likely ultimately targeting changes in cellular and tissue physiology that are mediated via similar receptors, natural progesterone has the potential to alter outcomes in patients who are at risk like 17-OHPC. Clinical trials that have applied a prophylactic strategy in women with a history of preterm birth likely have enrolled heterogeneous groups of women with differing pathways that led to their birth histories which may explain some variation in trial findings. The negative progesterone trial by O’Brien et al42 was not powered to assess efficacy in the subpopulation of women with a history of mid-trimester preterm birth and selection bias that was related to cervical length measurement at enrollment likely reduced the number of women who could respond to the intervention.
Indications for vaginal progesterone and 17-OHPC
A history of preterm birth, a sonographic short cervix, or both clinical problems have served to provide indication for this intervention.49 As noted previously, women at highest risk with a history of mid-trimester preterm birth should undergo prophylaxis with a progestogen. However, women with a history of later spontaneous preterm birth in the third trimester may not require this intervention. O’Brien et al42 and DeFranco et al50 evaluated treatment response in the largest randomized trial performed to date in singletons. In this study, prevention of recurrent preterm birth was not demonstrated with progesterone treatment based on historic factors alone, but a treatment response was identified when cervical length was used to stratify the population.50 This investigation identified a therapeutic effect to prolong gestation in women with a history of preterm birth who had a cervical length of ≤30 mm (n = 116; P = .04). Therefore, women with a history of spontaneous preterm birth in the third trimester who undergo cervical surveillance and have a cervical length >30 mm may not benefit because a positive treatment response has not been replicated for this subpopulation.
The importance of cervical length in defining the indication for treatment in asymptomatic patients has been verified by 2 other phase III trials that tested a universal screening strategy. Fonseca et al41 and Hassan et al51 demonstrated that treatment indicated for a sonographic short cervix can reduce the rate of early preterm birth in women who undergo a universal screening strategy by transvaginal ultrasound scanning. Romero et al43 also quantified a 42% reduction using this strategy in an individual patient-level metaanalysis. Unfortunately, 2 large trials that tested 17-OHPC in asymptomatic women with a short cervix did not identify benefit in groups with either a high-risk or low-risk profile for preterm birth.52 and 53 Furthermore, the study by Grobman et al52 did not observe a therapeutic effect in the subpopulation of low-risk women with the shortest cervical lengths, <15 mm. Rozenberg et al54 also did not demonstrate benefit with 17-OHPC exposure in a randomized trial of symptomatic patients with a short cervix. Therefore, vaginal progesterone appears to be the superior progestogen for women with a sonographic short cervix. Other biomarkers in concert with cervical length measurement ultimately may facilitate a better definition for treatment indication and of treatment response.
The most confident conclusion that can be made from randomized trials that have been performed to date is that prophylactic progestogen exposure in women with a multiple gestation in unselected cohorts is ineffective and potentially harmful when 17-OHPC is used as the intervention.55, 56, 57, 58, 59, 60, 61, 62, 63, 64, and 65 Numerous phase III trials have all failed to demonstrate positive results for their primary endpoints. Further study of a prophylactic strategy with vaginal progesterone in multiples without risk stratification is not warranted.
Other populations with negative results from larger trials include symptomatic cohorts with preterm contractions or premature rupture of the membranes.66 and 67 However, 2 metaanalyses that synthesized data from smaller trials have suggested progestogens may be beneficial in symptomatic populations with preterm labor.68 and 69 Additional larger trials are necessary to better assess the efficacy of supplemental progesterone in women with preterm labor; treatment is not recommended in symptomatic populations until such studies are performed.
A summary of clinical investigations to date is presented in the Box. Three important constructs regarding an indication for treatment are derived from the present data: (1) defining an indication for treatment primarily based on a biomarker in the ongoing pregnancy is likely optimal to basing therapy solely on obstetric history for the majority of patients, except for those at highest risk (a previous mid-trimester spontaneous preterm birth), (2) vaginal natural progesterone appears superior to 17-OHPC for efficacy in asymptomatic patients with a short cervix, and (3) women with a multiple gestation and symptomatic patients do not respond to this therapeutic strategy like asymptomatic singleton cohorts. The strength of recommendation for the use of progestogens to prevent preterm birth is based on the Grading of Recommendations Assessment, Development, and Evaluation guidelines (Box), and the present review is the first to assess this treatment strategy using these suggested guidelines.70
a Level of recommendation is based on data that were derived preferentially from phase III trials with the application of the Grading of Recommendations Assessment, Development, and Evaluation criteria.
O’Brien. Progestogen safety and efficacy to prevent preterm birth. Am J Obstet Gynecol 2016.
Prophylactic treatment may be considered and offered to women with a singleton pregnancy and who have a history of preterm birth in the third trimester, based on the single study by Meis et al38 while awaiting confirmatory phase III data. Additional trials of progestogens are needed to assess (1) the comparable efficacy between progestogens to validate the findings of Maher et al, (2) whether dosing should be increased at differing gestational ages such as the start of the third trimester to improve efficacy, and (3) safety.
Are vaginal progesterone and 17-OHPC equally safe?
Therapeutics aimed to prevent preterm birth such as tocolytics have limited efficacy once symptoms develop, necessitating earlier interventions. Current indications for supplemental progestogens to prevent preterm birth include populations that will most probably deliver at term. Consequently, a high margin of safety is required because these medications will be administered to pregnant women who are not experiencing potential benefit but who are undergoing a prolonged exposure.
The FDA review of 17-OHPC raised a safety concern based on the data from the trial by Meis et al.71 The Agency performed a survival analysis that generated Kaplan-Meier curves for the control and intervention groups that documented a cross-over event (Figure). The FDA has required labeling that acknowledges an increase in miscarriage was observed with this treatment from this trial. An early metaanalysis supported safety concerns related to the synthetic, as have more recent reviews, especially in women with a multiple gestations.72 and 73 In a secondary analysis derived from patients who were enrolled in the trial by Meis et al,38 an increased risk for preterm birth was observed in subpopulations that were discriminated by progesterone receptor genotype. Manuck et al26 demonstrated that particular haplotype blocks (Rs503362|rs666553 and Rs578029|rs666553) were associated with an adjusted odds ratio >10 for preterm birth <32 weeks gestation with exposure to 17-OHPC in the white/Hispanic subpopulation (adjusted odds ratio, 13.98 [95% CI, 1.27–153.32] and 16.19 [95% CI, 1.27–206.77], respectively). Differences were observed by race in this study, and further pharmacogenomic investigation of treatment response by race is needed.
Larger studies and metaanalyses have documented harm with exposure to progestogens, particularly in subpopulations at greater risk (Table). A trial level metaanalysis by Sotiriadis et al55 quantified a risk for harm related to 17-OHPC exposure in multiple gestations (RR, 1.21; 95% CI, 1.03–1.43), for a composite outcome of death and severe morbidity. The number needed to harm was 31 (95% CI 17–167). A recently published participant-level metaanalysis validated this concern for increased adverse outcomes.56 This study by Schuit et al56 found women who initiated 17-OHPC treatment at <24 weeks gestation had a higher rate of adverse outcomes (82/518 (16%) vs control subjects 60/512 (12%); RR, 1.4; 95% CI, 1.26–1.5). A significant increase in composite adverse outcome was also identified in the subpopulation with a longer cervix, >25 mm, at enrollment. This metaanalysis concluded that 17-OHPC should not be prescribed to women with a multiple gestation. Therefore, evidence for harm should be incorporated into prescribing decisions, and a mechanistic assessment of safety concerns should direct further research.
|Trial||Drug (dose)||Significant finding at secondary analysis||Data and/or significance|
|Combs et al61||17-Hydroxyprogesterone caproate (250 mg/wk)||Increased previable delivery||13/168 (8%) 17-OHPC vs 0/75 (0%); P = .01|
|Increased perinatal death||19/168 (11%) 17-OHPC vs 2/75 (3%); P = .05|
|Caritis et al62||17-Hydroxyprogesterone caproate (250 mg/wk)||Increase in birthweight <1500 grams||91/212 (43%) 17-OHPC vs 46/183 (25%); relative risk, 1.7 (95% confidence interval, 1.1–2.7)|
|Combs et al63||17-Hydroxyprogesterone caproate (250 mg/wk)||Shorter duration of pregnancy||Kaplan-Meier; P = .02|
|Increase in birthweight <2500 grams||195/320 (61%) 17-OHPC vs 70/156 (45%); P = .009|
|Birthweight, grams||2321 ± 523 17-OHPC vs 2469 ± 543; P = .03|
|Oxygen use at 28 days||9/308 (3%) 17-OHPC vs 0/150; P = .03|
|Lim et al57||17-Hydroxyprogesterone caproate (250 mg/wk)||Severe respiratory distress syndrome in neonates||82/681 (12%) 17-OHPC vs 51/674 (8%); relative risk, 1.55 (95% confidence interval, 1.01–2.37)|
|Earlier gestational age of membrane rupture, weeks||31.1 ± 6.1 17-OHPC vs 33.9 ± 4.0; P = .04|
|Senat et al58||17-Hydroxyprogesterone caproate (1000 mg/wk)||Increased preterm birth <32 weeks gestation||24/82 (29%) 17-OHPC vs 10/83 (12%); P = .007|
|Earlier gestational age at delivery||34+6 (31+4-36+3) 17-OHPC vs 35+3 (34+0 to 36+6); P = .029|
|Increased perinatal mortality rate75||9/158 (6%) 17-OHPC vs 1/154 (0.6%); P = .02|
|Composite adverse outcome of stillbirth plus respiratory distress75||55/160 (34%) 17-OHPC vs 34/154 (22%); P = .016|
|Rouse et al64||17-Hydroxyprogesterone caproate (250 mg/wk)||Negative correlation between 17-Hydroxyprogesterone caproate concentration and gestational age at delivery19||Hazard ratio 1.14; P = .001; R2 =.49|
|Meis et al38||17-Hydroxyprogesterone caproate (250 mg/wk)||Women with particular polymorphisms for progesterone receptors may have increased frequency of preterm birth with exposure26|
|rs503362 (white/Hispanic <32 weeks)||Adjusted odds ratio, 13.98 (95% confidence interval, 1.27–153.32)|
|rs578029 (white/Hispanics <32 weeks)||Adjusted odds ratio, 16.19 (95% confidence interval, 1.27–206.77)|
|Martinez de Tejada et al67||Progesterone (200 mg/day)||Symptomatic women with preterm labor, spontaneous preterm birth <34 weeks gestation||74/180 (40%) progesterone vs 48/168 (28.6%); P = .03|
17-OHPC, 17-hydroxyprogesterone caproate.
O’Brien. Progestogen safety and efficacy to prevent preterm birth. Am J Obstet Gynecol 2016.
The safety of 17-OHPC exposure in this population can also be evaluated by application of the Bradford Hill criteria to the body of evidence.74 One of these 9 criteria includes evaluation of dose response. The duration of pregnancy in multiples has been related significantly inversely to the serum 17-OHPC concentration, (hazard ratio, 1.14; P = .001).19 A dose-response for adverse outcomes in multiple gestations is also suggested by comparison of trials that tested 17-OHPC. The largest trial to date in multiples that evaluated prophylactic 17-OHPC was performed by Lim et al57 who used a dose of 250 mg/wk. These investigators found a significant increase in severe respiratory distress with exposure to the synthetic (RR, 1.55; 95% CI, 1.01–2.37). A study by Senat et al58 used a dose of 500 mg 17-OHPC twice per week in women with a twin gestation and a short cervix. They unfortunately observed a 2.4-fold increase in early preterm birth at <32 weeks gestation in the intent-to-treat analysis (24/82 (29%) treated vs 10/79 (12%) control; P = .007). A significant increase in perinatal mortality rate and a composite adverse outcome of stillbirth plus respiratory distress were associated with treatment.75
Other phase III trials in multiple gestations have suggested potential benefit rather than harm with exposure to progestogens. Norman et al59 observed a reduction in cesarean delivery and operative vaginal delivery with progesterone use. Rode et al60 demonstrated a reduction in emergency cesarean delivery and a significant reduction in birthweight of <1500 g in their monochorionic subgroup. Subpopulations at greater risk for suspected decidual/placental pathophysiologic conditions may be appropriate for future study with natural progesterone. Of interest, the only trial that did not identify harm with exposure to 17-OHPC in a twin gestation, the PROGESTWIN trial, recently found a significant increase in birthweight, a decrease in frequency of birthweight <1500 g, and a decrease in composite neonatal morbidity with treatment.76 The mean gestational age at delivery for the placebo group was 34.6 ± 3.8 weeks gestation in this study, which could indicate a higher risk profile of participants that deserves further evaluation.
Whether asymptomatic patients with a multiple gestation and short cervix (<24 weeks gestation) could benefit from supplemental progesterone has been suggested by 2 participant-level metaanalyses and a recently published randomized trial.43, 56, and 77 El-refaie et al77 randomly assigned 250 women with a cervical length of 20-25 mm between 20-24 weeks of gestation. The rates of respiratory distress syndrome, mechanical ventilation, and early neonatal death were reduced significantly with treatment. However, a retrospective study by Brubaker et al78 suggested caution in this population because of safety concerns. Given the safety profile of progestogen exposure in multiples, additional phase III trials are necessary, and any future trial should assess treatment response thoroughly by interrogating multiple biomarkers.
Structural teratogenicity has not been observed with early exposure to progestogens.79 and 80 Mechanisms for harm related to exposure later in gestation will likely involve alteration of progesterone receptor activity. Because these receptors are located within the central nervous system of the developing fetus, functional abnormalities such as behavioral teratogenicity requires further investigation. Basic science investigations have raised plausible concerns for such developmental abnormalities particularly for the synthetic drug.81 and 82 However, to date, no longer term adverse harms have been identified after exposure to either of these medications, but the data are limited.60, 83, 84, and 85
Based on present data that were derived from phase III trials and metaanalysis, natural progesterone appears to be the safer progestogen, but plausible concerns for adverse outcomes with exposure remain. Safety for an intervention in any obstetric population is more probable when natural agents are administered at doses that yield exposures within boundaries observed in human reproduction.86 Robust dose-response studies have yet to be performed and should be designed carefully. Also, this treatment strategy undoubtedly will be applied to other populations who are at risk for adverse events, such as women with an episode of preterm labor. Animal data have demonstrated the potential for adverse events, which include death, when supplemental progestogens are administered in models for preterm labor.87 Of concern, a recent trial in symptomatic women with an episode of preterm labor demonstrated that supplemental natural progesterone was associated with a significant increase in spontaneous preterm birth at <34 weeks gestation (74/180 (40%) vs 48/168 (29%); RR, 1.4; 95% CI, 1.04–1.88; P = .03; per protocol analysis).67 Hence, in symptomatic women, biomarkers that augment cervical assessment, particularly those that describe infectious/inflammatory pathways, may be essential to help guide safer exploration of the efficacy of supplemental progestogens.
Risk/benefit and cost of progestogen use
Vaginal progesterone indicated for a sonographic short cervix is the first drug to demonstrate reproducible efficacy for the prevention of early preterm birth in independent phase III trials. The number of patients needed to screen to prevent 1 early preterm birth (<34 weeks gestation) has been estimated as 125 (95% CI, 88–288), and the number needed to screen to prevent a case of major neonatal morbidity/death has been quantified as 225 (95% CI, 150–1013; calculated for treatment of women with a cervical length of ≤25 mm).49 The proposed indications in the Box for progestogen use mimic the maturation of indication observed with cervical cerclage by focusing more on cervical length than obstetric history.88 and 89 Despite the success of vaginal progesterone and cerclage in women with a short cervix, other treatments are needed to further reduce the sequelae of early preterm birth. A poor treatment response to progestogen therapy has not been defined (eg, progressive marked cervical shortening). Adjuvant interventions that use biomechanical strategies or medications that further alter the inflammatory milieu deserve evaluation in well-selected higher risk groups, based on biomarkers that suggest a poor treatment response.90 and 91
Intramuscular therapy with 17-OHPC has the advantage to document compliance that is important for treatment response.51 Additional large pragmatic trials may better define the comparative effectiveness of these drugs as they are used in clinical practice. Methods to enhance compliance with vaginal treatment are needed. However, the treatment response to 17-OHPC appears to vary based on the gestational age of the previous preterm birth, whether a term birth has occurred, maternal weight, and serum concentration.45, 92, 93, 94, and 95 Such a variable response explains, in part, the substantial heterogeneity that was noted in the Cochrane review of progestogens to prevent recurrent early preterm birth.96
Results from the confirmatory PROLONG trial are expected relatively soon. This trial will enroll women at 16-20+6 weeks gestation with a history of spontaneous preterm birth (20-36 weeks gestation) and prophylactically expose them to either weekly 17-OHPC (250 mg) or placebo. Because of its estimated sample size of approximately 1700 participants, this trial will be important in defining the direction for progestogen treatment. A positive trial with evidence of safety will validate the approach and emphasize prophylaxis for women with a history of preterm birth that occurred over a wide gestational age range (20-36 weeks). The PROLONG trial may also find that benefit is limited to a select subpopulation such as those with a history of mid-trimester preterm birth. However, a negative trial should not negate the therapeutic benefits that have been identified with vaginal progesterone because these progestogens are different drugs with differing pharmacodynamics. Given the importance of this trial, its results should be forwarded to the obstetric community as early as possible.
Progestogen treatment indicated for a short cervix is cost-effective.13, 14, 97, and 98 An updated investigation by Werner et al98 again demonstrated the cost-effectiveness of this treatment strategy. Further savings are possible by the avoidance of treatment in women with a history of third-trimester preterm birth and who have the longest cervical lengths.50 Cost-benefit has become more germane because the compounding of 17-OHPC is being curtailed by the FDA.99
Although the FDA has responsibility for the marketing of products in the United States, professional organizations in obstetrics have a greater influence on practice. Most medications in obstetrics that demonstrate efficacy (eg, corticosteroids for fetal lung maturity, magnesium for neuroprotection, and others) are not approved by the FDA.1 Practice guidelines that address newer interventions, such as progestogen use, should be reassessed frequently because the development of therapeutics in obstetrics rarely proceeds along common regulatory pathways, which increases uncertainty. Select basic principles for the assessment of efficacy are common to the application of the Grading of Recommendations Assessment, Development, and Evaluation guidelines and the evaluation of new drugs by the FDA.100 Such evaluations temporarily may influence the practice of obstetrics differently; however, the inevitable direction for therapeutics in obstetrics is toward a better appreciation of pathophysiologic conditions, better targeting of pathophysiologies through the use of biomarkers, and use of the safest treatments. Remarkably, the first intervention to demonstrate a significant reduction reproducibly in early preterm birth in phase III trials fulfills these important objectives. Recent data that evaluated the pharmacodynamics, safety, and efficacy of progestogens provides important new information regarding the optimal use or avoidance of these medications that should alter current recommendations.
- 1 R. Romero, L. Yeo, J. Miranda, et al. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med. 2013;41:27-44
- 2 D.F. Lewis, S.L. Baker, R. Stauffer. Short cervix and vaginal progesterone: a model on how to tackle the problem of idiopathic preterm labor. J Reprod Med. 2013;58:434-437
- 3 Society for Maternal Fetal Medicine publications committee, with assistance of Berghella V. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol. 2012;206:376-386
- 4 ACOG Committee on Practice Bulletins—Obstetrics. Prediction and prevention of preterm birth. Obstet Gynecol. 2012;120:964-973
- 5 J.D. Iams. Prevention of preterm parturition. N Engl J Med. 2014;370:254-261
- 6 B.M. Mercer, R.L. Goldenberg, A.H. Moawad, et al. The Preterm Prediction Study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. Am J Obstet Gynecol. 1999;181:1216-1221
- 7 C.Y. Spong. Prediction and prevention of recurrent spontaneous preterm birth. Obstet Gynecol. 2007;110:405-415
- 8 C.V. Ananth, D. Getahun, M.R. Peltier, H.M. Salihu, A.M. Vintzileos. Recurrence of spontaneous versus medically indicated preterm birth. Am J Obstet Gynecol. 2006;195:643-650
- 9 S. Mazaki-Tovi, R. Romero, J.P. Kusanovic, et al. Recurrent preterm birth. Semin Perinatol. 2007;31:142-158
- 10 J.D. Iams, R.L. Goldenberg, P.J. Meis, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development. N Engl J Med. 1996;334:567-572
- 11 V. Berghella, A. Roman, C. Daskalakis, A. Ness, J.K. Baxter. Gestational age at cervical length measurement and the incidence of preterm birth. Obstet Gynecol. 2007;110:311-317
- 12 R.L. Goldenberg, J. Iams, M. Miodovnik, et al. The preterm prediction study: risk factors in twin gestation: National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol. 1996;175:1047-1053
- 13 A.G. Cahill, A.O. Odibo, A.B. Caughey, et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol. 2010;202:548.e1-548.e8
- 14 E.F. Werner, C.S. Hans, C.M. Pettker, et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultrasound Obstet Gynecol. 2011;38:32-37
- 15 Mills AA, Yonish B, Feng L, Schomberg DW, Heine RP, Murtha AP. Characterization of progesterone receptor isoform expression in fetal membranes. 2006;195:998-1003.
- 16 A.P. Murtha, L. Feng, B. Yonish, P.C. Leppert, D.W. Schomberg. Progesterone protects fetal chorion and maternal decidua cells from calcium-induced death. Am J Obstet Gynecol. 2007;196:257.e1-257.e5
- 17 R.A. Word, X.H. Li, M. Hnat, K. Carrick. Dynamics of cervical remodeling during pregnancy and parturition: mechanisms and current concepts. Semin Reprod Med. 2007;25:69-79
- 18 J.M. O’Brien. Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens. Ultrasound Obstet Gynecol. 2013;42:247-253
- 19 S.N. Caritis, H.N. Simhan, Y. Zhao, et al. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation. Am J Obstet Gynecol. 2012;207:396.e1-396.e8
- 20 C. Nold, M. Maubert, L. Anton, S. Yellon, M.A. Elovitz. Prevention of preterm birth by progestational agents: what are the molecular mechanisms?. Am J Obstet Gynecol. 2013;208:223.e1-223.e7
- 21 S. Aksel, R. Yoeman, J. Hazelton, et al. Effects of 17-hydroxyprogesterone caproate (17-OHPC) administration in pregnant squirrel monkeys. Am J Primatol. 1991;25:175-183
- 22 C.D. Cuppett, Y. Zhao, S. Caritis, et al. Effect of endogenous steroid hormones on 17-alpha-hydroxyprogesterone caproate metabolism. Am J Obstet Gynecol. 2013;208:86.e1-86.e6
- 23 B. Attardi, A. Zeleznik, H. Simhan, J.P. Chiao, D.R. Mattison, S.N. Caritis. Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins. Am J Obstet Gynecol. 2007;197:599.e1-599.e7
- 24 H. Xu, J.M. Gonzalez, E. Ofori, M.A. Elovitz. Preventing cervical ripening: the primary mechanism by which progestational agents prevent preterm birth?. Am J Obstet Gynecol. 2008;198:314.e1-314.e8
- 25 A.K. Sfakianaki, E.R. Norwitz. Mechanisms of progesterone action in inhibiting prematurity. J Matern Fetal Neonatal Med. 2006;19:763-772
- 26 T.A. Manuck, Y. Lai, P.J. Meis, et al. Progesterone receptor polymorphisms and clinical response to 17-alphahydroxyprogesterone caproate. Am J Obstet Gynecol. 2011;205:135.e1-135.e9
- 27 A.E. Fucron, R. Romero, O. Plazyo, et al. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has anti-inflammatory effects at the murine maternal-fetal interface. Am J Obstet Gynecol. 2015; Epub ahead of print
- 28 R. Smith, J.I. Smith, X. Shen, et al. Patterns of plasma corticotrophin-releasing hormone, progesterone, estradiol, and estriol change and the onset of human labor. J Clin Endocrinol Metab. 2009;94:2066-2094
- 29 N.K. Ruddock, S.Q. Shi, S. Jain, et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol. 2008;199:391.e1-391.e7
- 30 D. Kumar, E. Springel, R.M. Moore, et al. Progesterone inhibits in vitro fetal membrane weakening. Am J Obstet Gynecol. 2015;213:520.e1-520.e9
- 31 J.M. O’Brien, E.A. DeFranco, C.D. Adair, et al. for the Progesterone Vaginal Gel Study Group. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2009;34:653-659
- 32 F. Facchinetti, S. Paganelli, G. Comitini, G. Dante, A. Volpe. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007;196:453.e1-453.e4
- 33 C. Pessel, S. Moni, N. Zork, et al. The effect of intramuscular progesterone on the rate of cervical shortening. Am J Obstet Gynecol. 2013;209:269.e1-269.e7
- 34 C.P. Durnwald, C.D. Lynch, H. Walker, J.D. Iams. The effect of treatment with 17 alpha- hydroxyprogesterone caproate on changes in cervical length over time. Am J Obstet Gynecol. 2009;201:410.e1-410.e5
- 35 J.M. O’Brien, S.J. Ho, N. Istwan, D.L. Rhea, G.J. Stanziano, J.R. Barton. Uterine activity in women receiving 17alpha-hydroxyprogesteronecaproate for preterm birth prevention: an observational study. Am J Perinatol. 2010;27:157-162
- 36 E.B. da Fonseca, R.E. Bittar, M.H. Carvalho, M. Zugaib. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188:419-424
- 37 R. Romero, F.Z. Stanczyk. Progesterone is not the same as 17-hydroxyprogesterone caproate: implications for obstetrical practice. Am J Obstet Gynecol. 2013;208:421-426
- 38 P.J. Meis, M. Klebanoff, E. Thom, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348:2379-2385
- 39 US Food and Drug Administration. Background document for meeting of advisory committee for reproductive health drugs, January 20, 2012. Available at: www.fda.gov/downloads/advisorycommittees/committeemeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm287987.pdf. Accessed: January 27, 2012.
- 40 L.A. McKay, T.R. Holford, M.B. Bracken. Re-analysis of the PREGNANT trial confirms that vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix. Ultrasound Obstet Gynecol. 2014;43:596-597
- 41 E.B. Fonseca, E. Celik, M. Parra, M. Singh, K.H. Nicolaides. Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357:462-469
- 42 J.M. O’Brien, C.D. Adair, D.F. Lewis, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2007;30:687-696
- 43 R. Romero, K.H. Nicolaides, A. Conde-Agudelo, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and meta-analysis of individual patient data. Am J Obstet Gynecol. 2012;206:124.e1-124.e19
- 44 M.A. Maher, A. Abdelaziz, M. Ellaithy, M.F. Bazeed. Prevention of preterm birth: a randomized trial of vaginal compared to intramuscular progesterone. Acta Obstet Gynecol Scand. 2013;92:215-222
- 45 S.N. Caritis, R. Venkataramanan, E. Thom, et al. Relationship between 17-alphahydroxyprogesterone caproate concentration and spontaneous preterm birth. Am J Obstet Gynecol. 2014;210:128.e1-128.e6
- 46 S.N. Caritis, S. Sharma, R. Venkataramanan, et al. Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. Am J Obstet Gynecol. 2012;207:398.e1-398.e8
- 47 E. Cicinelli, D. DeZiegler, C. Bulletti, M.G. Matteo, L.M. Schonauer, P. Galantino. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403-406
- 48 R.A. Miles, R.J. Paulson, R.A. Lobo, M.F. Press, L. Dahmoush, M.V. Sauer. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994;62:485-490
- 49 A. Conde-Agudelo, R. Romero. Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: clinical and public health implications. Am J Obstet Gynecol. 2015; Epub ahead of print
- 50 E.A. DeFranco, J.M. O’Brien, C.D. Adair, et al. Vaginal progesterone is associated with a decreased risk of early preterm birth and improved neonatal outcome in women with a short cervix. Ultrasound Obstet Gynecol. 2007;30:697-705
- 51 S.S. Hassan, R. Romero, D. Vidyadhari, et al. for the PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographically short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol. 2011;38:18-31
- 52 W.A. Grobman, E.A. Thom, C.Y. Spong, et al. 17 Alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol. 2012;207:390.e1-390.e8
- 53 N. Winer, F. Bretelle, M.V. Senat, et al. 17 Alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2015;212:485.e1-485.e10
- 54 P. Rozenberg, A. Chauveaud, P. Deruelle, et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol. 2012;206:206.e1-206.e9
- 55 A. Sotiriadis, S. Papatheodorou, G. Makrydimas. Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis. Ultrasound Obstet Gynecol. 2012;40:257-266
- 56 E. Schuit, S. Stock, L. Rode, et al. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis. BJOG. 2015;122:27-37
- 57 A.C. Lim, E. Schuit, K. Bloemenkamp, et al. 17Alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. Obstet Gynecol. 2011;118:513-520
- 58 M.V. Senat, R. Porcher, N. Winer, et al. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2013;208:194.e1-194.e8
- 59 J.E. Norman, F. Mackenzie, P. Owen, et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet. 2009;373:2034-2040
- 60 L. Rode, K. Klein, K.H. Nicolaides, et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol. 2011;38:272-280
- 61 C.A. Combs, T. Garite, K. Maurel, A. Das, M. Porto, for the Obstetrix Collaborative Research Network. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol. 2010;203:248.e1-248.e9
- 62 S.N. Caritis, D.J. Rouse, A.M. Peaceman, et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Obstet Gynecol. 2009;113:285-292
- 63 C.A. Combs, T. Garite, K. Maurel, A. Das, M. Porto, Obstetrix Collaborative Research Network. 17-Hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol. 2011;204:221.e1-221.e8
- 64 D.J. Rouse, S.N. Caritis, A.M. Peaceman, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357:454-461
- 65 M.L. Brizot, W. Hernandez, A.W. Liao, et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2015;213:82.e1-82.e9
- 66 C.A. Combs, T.J. Garite, K. Maurel, et al. 17-Hydroxyprogesterone caproate for preterm rupture of the membranes; a multicenter, randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2015;213:364.e1-364.e12
- 67 B. Martinez de Tejada, A. Karolinski, M.C. Ocampo, et al. for the 4P trial group. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG. 2015;122:80-93
- 68 A. Suhag, G. Saccone, V. Berghella. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol. 2015;213:479-487
- 69 G. Saccone, A. Suhag, V. Berghella. 17-Alphahydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. Am J Obstet Gynecol. 2015;213:16-22
- 70 Society of Maternal-Fetal Medicine (SMFM). Chauhan SP, Blackwell SC. SMFM adopts GRADE (Grading of Recommendations Assessment, Development, and Evaluation) for clinical guidelines. Am J Obstet Gynecol. 2013;209:163-165
- 71 Food and Drug Administration. 17α-Alpha hydroxyprogesterone caproate for prevention of preterm birth: overview of FDA background document. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4227B1-02-01-FDA-Background.pdf Accessed: July 13, 2007.
- 72 J.M. O’Brien, D.F. Lewis. Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies. J Reprod Med. 2009;54:73-87
- 73 J.M. O’Brien. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment. Am J Perinatol. 2012;29:665-672
- 74 J.M. O’Brien. Progestogen safety in multiple gestations: application of the Bradford Hill criteria. BJOG. 2015;122:610-614
- 75 J.M. O’Brien. Mortality related to 17-OHPC exposure is an important safety outcome. Am J Obstet Gynecol. 2013;209:282-283
- 76 J. Awwad, I.M. Usta, G. Ghazeeri, et al. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity. BJOG. 2015;122:71-79
- 77 W. El-refaie, M. Abdelhafez, A. Badawy. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet. 2015; Epub ahead of print
- 78 S.G. Brubaker, C. Pessel, N. Zork, C. Gyamfi-Bannerman, C.V. Ananth. Vaginal progesterone in women with twin gestations complicated by short cervix: a retrospective cohort study. BJOG. 2015;122:712-718
- 79 Z. Katz, M. Lancet, J. Skornik, J. Chemke, B.M. Mogilner, M. Klinberg. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol. 1985;65:775-780
- 80 I. Dudas, J. Gidai, A.E. Czeizel. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom Kyoto. 2006;46:194-198
- 81 J. Willing, C.K. Wagner. Exposure to the synthetic progestin, 17alpha-hydroxyprogesterone caproate during development impairs cognitive flexibility in adulthood. Endocrinology. 2015; 10.1210/en.2015-1775
- 82 C.K. Wagner. Progesterone receptors and neural development: a gap between bench and bedside?. Endocrinology. 2008;149:2743-2749
- 83 A.T. Norman, G.S. Norman, K. Anderson, et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol. 2007;110:865-872
- 84 H.C. McNamara, R. Wood, J. Chalmers, et al. STOPPIT baby follow-up study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One. 2015;10:e0122341
- 85 J.M. O’Brien, J.J. Steichen, J.A. Phillips, G.W. Creasy. Two year infant outcomes for children exposed to supplemental progesterone gel in utero: secondary analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2012;206(suppl):S223
- 86 E.R. Simpson, P.C. MacDonald. Endocrine physiology of the placenta. Ann Rev Physiol. 1981;43:163-188
- 87 M.A. Elovitz, C. Mrinalini. The use of progestational agents for preterm birth: lessons from a mouse model. Am J Obstet Gynecol. 2006;195:1004-1010
- 88 American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 142: Cerclage for the management of cervical insufficiency. Obstet Gynecol. 2014;123:372-379
- 89 V. Berghella, A.O. Odibo, M.S. To, O.A. Rust, S.M. Althuisius. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data. Obstet Gynecol. 2005;106:181-189
- 90 M. Goya, L. Pratcorona, C. Merced, et al. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomized controlled trial. Lancet. 2012;379:1800-1806
- 91 E.S. Miller, W.A. Grobman, L. Fonseca, B.K. Robinson. Indomethacin and antibiotics in examination-indicated cerclage: a randomized trial. Obstet Gynecol. 2014;123:1311-1316
- 92 J.R. Barton, L.A. Barton, N.B. Istwan, D.J. Rhea, C.N. Desch, B.M. Sibai. 17-αHydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?. Am J Obstet Gynecol. 2011;205:269.e1-269.e6
- 93 K.D. Heyborne, A.A. Allhouse, J.C. Carey. Does 17-alphahydroxyprogesterone caproate prevent recurrent preterm birth in obese women. Am J Obstet Gynecol. 2015; Epub ahead of print
- 94 A.L. Co, H.C. Walker, E.M. Hade, J.D. Iams. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate. Am J Obstet Gynecol. 2015;213:233.e1-233.e5
- 95 C.Y. Spong, P.J. Meis, E.A. Thom, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol. 2005;193:1127-1131
- 96 J.M. Dodd, L. Jones, V. Flenady, R. Cincotta, C.A. Crowther. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev. 2013;7:CD004947
- 97 L.T. Pizzi, N.S. Seligman, J.K. Baxter, E. Jutkowitz, V. Berghella. Cost and cost effectiveness of vaginal progesterone gel in reducing preterm birth: an economic analysis of the PREGNANT trial. Pharmacoeconomics. 2014;32:467-478
- 98 E.F. Werner, M.S. Hamel, K. Orzechowski, V. Berghella, S.F. Thung. Cost-effectiveness of transvaginal ultrasound cervical length screening in singletons without a prior preterm birth: an update. Am J Obstet Gynecol. 2015;213:554.e1-554.e6
- 99 Food and Drug Administration. Hydroxyprogesterone caproate. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm402614.htm. Accessed: December 11, 2014.
- 100 G.H. Guyatt, A.D. Oxman, G. Vist, et al., for the GRADE Working Group. Rating the quality of evidence and strength of recommendations GRADE: an emerging consensus on rating the quality of evidence and strength of recommendations. BMJ. 2008;336:924-926
a University of Kentucky, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Lexington, KY
b University of South Alabama, Department of Obstetrics and Gynecology, Mobile, AL
∗ Corresponding author: John M. O’Brien, MD.
J. M. O’Brien was involved in studies of progesterone gel treatment for preterm birth prevention sponsored by a maker of progesterone gel; he served on Advisory Boards and as Consultant for Watson Pharmaceuticals, a company with a financial interest in marketing vaginal progesterone gel for preterm birth prevention; he and others are listed in a patent on the use of progesterone compounds to prevent preterm birth (USA Patent Number 7884093: Progesterone for the Treatment and Prevention of Spontaneous Preterm Birth). He has received other patents and has applications pending for devices to treat obstetrical patients including populations at increased risk for preterm birth. He has not received any funds from a royalty agreement or licensing of any patent to date nor has his university. He was involved in studies as a principal investigator published in 2011 and 2007.
D.F. Lewis was a principal investigator in a study testing vaginal progesterone published in 2007 sponsored by Columbia Laboratories.
© 2016 Elsevier Inc., All rights reserved.